Synergism between endotoxin priming and exotoxin challenge in provoking severe vascular leakage in rabbit lungs.
Lipopolysaccharides (LPS) of gram-negative bacteria prime rabbit lungs for enhanced thromboxane-mediated vasoconstriction upon subsequent challenge with the exotoxin Escherichia coli hemolysin (HlyA) (Walmrath et al. J. Exp. Med. 1994;180:1437-1443). We investigated the impact of endotoxin priming and subsequent HlyA challenge on lung vascular permeability while maintaining constancy of capillary pressure. Rabbit lungs were perfused in a pressure-controlled mode in the presence of the thromboxane receptor antagonist BM 13.505, with continuous monitoring of flow. Perfusion for 180 min with 10 ng/ml LPS did not provoke vasoconstriction or alteration of capillary filtration coefficient (Kfc) values. HlyA (0.021 hemolytic units/ml) induced thromboxane release and a transient decrease in perfusion flow in the absence of significant changes in Kfc. Similar results were obtained when LPS and HlyA were coapplied simultaneously. However, when the HlyA challenge was undertaken after 180 min of LPS priming, a manifold increase in Kfc values was noted, with concomitant severe lung edema formation, although capillary pressure remained unchanged. Thus, endotoxin primes the lung vasculature to respond with a severe increase in vascular permeability to a subsequent low-dose application of HlyA. Such synergism between endotoxin priming and exotoxin challenge in provoking lung vascular leakage may contribute to the pathogenesis of respiratory failure in sepsis and severe lung infection.
Schütte
H
H
Department of Internal Medicine, Justus-Liebig University, Giessen, Germany.
Rosseau
S
S
Czymek
R
R
Ermert
L
L
Walmrath
D
D
Krämer
H J
HJ
Seeger
W
W
Grimminger
F
F
D000818:Animals; D016470:Bacteremia / Q000150:complications; D001426:Bacterial Proteins / Q000009:adverse effects*; D002199:Capillary Permeability / Q000187:drug effects*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004926:Escherichia coli; D004927:Escherichia coli Infections / Q000150:complications; D029968:Escherichia coli Proteins; D015633:Extravascular Lung Water / Q000187:drug effects*; D005260:Female; D006460:Hemolysin Proteins / Q000009:adverse effects*; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000009:adverse effects*; D008297:Male; D010648:Phenylacetates / Q000494:pharmacology; D011652:Pulmonary Circulation / Q000187:drug effects; D011817:Rabbits; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D012131:Respiratory Insufficiency / Q000382:microbiology*; D013449:Sulfonamides / Q000494:pharmacology
D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D006460:Hemolysin Proteins; C036507:Hlya protein, E coli; D008070:Lipopolysaccharides; D010648:Phenylacetates; D017482:Receptors, Thromboxane; D013449:Sulfonamides; C051762:daltroban